Tigecycline as a ausative agent of severe hypoglycemia

Puca, Entela; Puca, Edmond; Vrekaj, Klei; Bitri, Sonila; Xhabija, Nereida

doi:10.1530/endoabs.90.ep1103

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this review, c-peptide levels during hypoglycemia were tested in 2 case reports and were within the normal range in one patient and elevated in the other. 15,16 It is worth mentioning that the patient with elevated c-peptide level was receiving repaglinide (half-life of 1-2 hours), which was stopped 24 hours before the onset of hypoglycemia.…”

Section: Discussionmentioning

confidence: 99%

“…Three of the 9 identified case reports were excluded from further consideration, 2 for nonrelevance and one as a duplicate publication. [14][15][16][17][18][19] Two of the 6 included case reports were published in full manuscripts, and the other 4 were published as conference abstracts. All patients described in the 6 case reports developed hypoglycemia while receiving the FDA-approved dose of tigecycline (100 mg loading followed by 50 mg every 12 hours).…”

Section: Case Reportsmentioning

confidence: 99%

“…A 54-year-old woman with Type 2 DM and endstage kidney disease on hemodialysis was admitted to the hospital for Staphylococcus epidermidis bacteremia. 16 The patient experienced a rapid onset of severe hypoglycemia 6 hours after the first dose of tigecycline, followed by multiple hypoglycemia events (blood glucose levels 2.2-2.6 mmol/L [39.6-46.8 mg/dL]) over a period of 16 hours. No information was provided regarding concomitant insulin administration or other antidiabetic agents before hypoglycemia events.…”

Section: Case Reportsmentioning

confidence: 99%

See 2 more Smart Citations

Tigecycline and Hypoglycemia, When and How?

Hakeam,

Sarkhi,

Iansavichene

2023

Journal of Pharmacy Technology

View full text Add to dashboard Cite

Objective: To describe the clinical characteristics of hypoglycemia that develop with tigecycline therapy and to review and summarize the current evidence of this uncommonly occurring metabolic adverse effect of tigecycline therapy. Underlying risk factors and potential mechanisms are also discussed. Data source: A 3-phase literature search was performed. In phase 1, the Cochrane Central Register of Controlled Trials (CENTRAL) Library, MEDLINE, and Embase electronic databases were searched for hypoglycemia and tigecycline, published from inception until August 2023. In phase 2, MEDLINE was searched for tigecycline randomized controlled trials and results were manually screened for hypoglycemia. In phase 3, the US Food and Drug Administration Adverse Event Reporting System public dashboard was searched for reports on tigecycline and hypoglycemia from June 2005 until July 2023. Study selection and data extraction: Relevant English-language citations and those conducted in humans were considered. Relevance to patient care and clinical practice: Hypoglycemia of various causes is an independent mortality risk. This review raises awareness among clinicians about the possibility of hypoglycemia with tigecycline therapy. Conclusion: Data on tigecycline-related hypoglycemia are scarce. Hypoglycemia may occur at any time during tigecycline therapy and can be severe and persist for days after tigecycline cessation. Renal dysfunction or renal replacement therapy may predispose to severe hypoglycemia during tigecycline therapy. Tigecycline-related hypoglycemia may develop in patients with or without diabetes mellitus and appears independent of insulin or antidiabetic agents. Intravenous dextrose showed efficacy in the restoration of euglycemia. Studies are needed to determine whether tigecycline-related hypoglycemia is iatrogenic or spontaneous.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Case Reportsmentioning

confidence: 99%

Section: Case Reportsmentioning

confidence: 99%

See 1 more Smart Citation